Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective.

Capehorn M, Johansson E, Davies A, Evans J, Godbeer F, van Hest N, Cotterill G, Tolley K

Advances in therapy11 Aug 2025Cited by 1 (Europe PMC)

PMID40788459PMCIDPMC12474619DOI10.1007/s12325-025-03288-3PepBankPUB-40788459

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study13

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone13

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Tirzepatide aloneIn silicoOther
In a lifetime simulation of people with obesity or overweight, all modeled tirzepatide doses were dominant to liraglutide; modeled tirzepatide doses were 5 mg, 10 mg and 15 mg versus liraglutide 3 mg.
In plain wordsIn obesity or overweight simulations, all modeled tirzepatide doses were dominant to liraglutide.
Peptide
Tirzepatide
Outcome
Not applicablecost-effectiveness in trial population
Study
n: not reported in source
lifetime simulation model
Comparator
liraglutide
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
In the trial population, all doses of tirzepatide were dominant to liraglutide, with estimated cost savings and QALY gains.
5 context sentences(design, population, supporting numbers)
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4078845901
02Computer modelNot a test of Tirzepatide aloneIn silicoOther
In a lifetime simulation of people with obesity or overweight, all modeled tirzepatide doses had estimated cost savings versus liraglutide; modeled tirzepatide doses were 5 mg, 10 mg and 15 mg versus liraglutide 3 mg.
In plain wordsIn obesity or overweight simulations, all modeled tirzepatide doses saved costs versus liraglutide.
Peptide
Tirzepatide
Outcome
Decreasecost savings in trial population
Study
n: not reported in source
lifetime simulation model
Comparator
liraglutide
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
In the trial population, all doses of tirzepatide were dominant to liraglutide, with estimated cost savings and QALY gains.
5 context sentences(design, population, supporting numbers)
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4078845902
03Computer modelNot a test of Tirzepatide aloneIn silicoOther
In a lifetime simulation of people with obesity or overweight, all modeled tirzepatide doses had estimated QALY gains versus liraglutide; modeled tirzepatide doses were 5 mg, 10 mg and 15 mg versus liraglutide 3 mg.
In plain wordsIn obesity or overweight simulations, all modeled tirzepatide doses gained QALYs versus liraglutide.
Peptide
Tirzepatide
Outcome
Increasequality-adjusted life year gains in trial population
Study
n: not reported in source
lifetime simulation model
Comparator
liraglutide
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
In the trial population, all doses of tirzepatide were dominant to liraglutide, with estimated cost savings and QALY gains.
5 context sentences(design, population, supporting numbers)
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4078845903
04Computer modelNot a test of Tirzepatide aloneIn silicoOther
In a lifetime simulation of liraglutide's UK recommended population, modeled tirzepatide versus liraglutide had estimated ICERs of £5401-7864 per QALY gained across doses.
In plain wordsIn simulations of liraglutide's UK recommended population, tirzepatide versus liraglutide had estimated ICERs of £5401-7864 per QALY across doses.
Peptide
Tirzepatide
Outcome
Direction not reportedincremental cost-effectiveness ratio in NICE recommended population
Study
n: not reported in source
lifetime simulation model
Comparator
liraglutide
Outcome group
Cost-effectiveness · Pharmacology
Measurements
ICER
5401 to 7864 £/QALY gained
across doses
Source sentences
Summary
In liraglutide's UK recommended population the estimated ICERs for tirzepatide vs liraglutide were £5401-7864/QALY gained across doses; the change in results is primarily due to the 2-year stopping rule for liraglutide in this population.
4 context sentences(design, population, supporting numbers)
Summary · context
A subgroup analysis was performed in liraglutide's National Institute of Health and Care Excellence (NICE) recommended population (patients with a BMI of ≥ 35 kg/m² with non-diabetic hyperglycaemia and a high risk of cardiovascular disease [CVD]).
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The subgroup analysis included a 2-year stopping rule for liraglutide to reflect the NICE reimbursement criteria.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4078845904
05Computer modelNot a test of Tirzepatide aloneIn silicoEfficacy outcome
In a lifetime simulation of two obesity or overweight populations, all modeled tirzepatide doses reduced knee replacements versus liraglutide; modeled tirzepatide doses were 5 mg, 10 mg and 15 mg versus liraglutide 3 mg.
In plain wordsIn simulations of obesity or overweight trial and UK recommended populations, tirzepatide reduced knee replacements versus liraglutide.
Peptide
Tirzepatide
Outcome
Decreaseknee replacements
Study
n: not reported in source
lifetime simulation model
Comparator
liraglutide
Outcome group
Bone and joint · Musculoskeletal
Measurements
reduction
29 to 46%
knee replacements
Source sentences
Summary
In both populations, all doses of tirzepatide demonstrated reductions in at least five of seven complications compared to liraglutide, most notably for knee replacements (29-46% reduction) and diabetes (25-48% reduction).
6 context sentences(design, population, supporting numbers)
Summary · context
A subgroup analysis was performed in liraglutide's National Institute of Health and Care Excellence (NICE) recommended population (patients with a BMI of ≥ 35 kg/m² with non-diabetic hyperglycaemia and a high risk of cardiovascular disease [CVD]).
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4078845905
06Computer modelNot a test of Tirzepatide aloneIn silicoEfficacy outcome
In a lifetime simulation of two obesity or overweight populations, all modeled tirzepatide doses reduced diabetes versus liraglutide; modeled tirzepatide doses were 5 mg, 10 mg and 15 mg versus liraglutide 3 mg.
In plain wordsIn simulations of obesity or overweight trial and UK recommended populations, tirzepatide reduced diabetes versus liraglutide.
Peptide
Tirzepatide
Outcome
Decreasediabetes
Study
n: not reported in source
lifetime simulation model
Comparator
liraglutide
Outcome group
Glycemic control · Metabolic and weight
Measurements
reduction
25 to 48%
diabetes
Source sentences
Summary
In both populations, all doses of tirzepatide demonstrated reductions in at least five of seven complications compared to liraglutide, most notably for knee replacements (29-46% reduction) and diabetes (25-48% reduction).
6 context sentences(design, population, supporting numbers)
Summary · context
A subgroup analysis was performed in liraglutide's National Institute of Health and Care Excellence (NICE) recommended population (patients with a BMI of ≥ 35 kg/m² with non-diabetic hyperglycaemia and a high risk of cardiovascular disease [CVD]).
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4078845906
07Computer modelNot a test of Liraglutide aloneIn silicoOther
In lifetime simulations of the obesity or overweight trial population, liraglutide was dominated by modeled tirzepatide.
In plain wordsIn obesity or overweight simulations, liraglutide was dominated by tirzepatide.
Peptide
Liraglutide
Outcome
Not applicablecost-effectiveness in trial population
Study
n: not reported in source
lifetime simulation model
Comparator
tirzepatide
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
In the trial population, all doses of tirzepatide were dominant to liraglutide, with estimated cost savings and QALY gains.
5 context sentences(design, population, supporting numbers)
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4078845907
08Computer modelNot a test of Liraglutide aloneIn silicoOther
In lifetime simulations of the obesity or overweight trial population, liraglutide had higher modeled costs than tirzepatide.
In plain wordsIn obesity or overweight simulations, liraglutide had higher costs than tirzepatide.
Peptide
Liraglutide
Outcome
Increasecosts in trial population
Study
n: not reported in source
lifetime simulation model
Comparator
tirzepatide
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
In the trial population, all doses of tirzepatide were dominant to liraglutide, with estimated cost savings and QALY gains.
5 context sentences(design, population, supporting numbers)
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4078845908
09Computer modelNot a test of Liraglutide aloneIn silicoOther
In lifetime simulations of the obesity or overweight trial population, liraglutide had fewer modeled QALYs than tirzepatide.
In plain wordsIn obesity or overweight simulations, liraglutide had fewer quality-adjusted life years than tirzepatide.
Peptide
Liraglutide
Outcome
Decreasequality-adjusted life years in trial population
Study
n: not reported in source
lifetime simulation model
Comparator
tirzepatide
Outcome group
Cost-effectiveness · Pharmacology
Source sentences
Summary
In the trial population, all doses of tirzepatide were dominant to liraglutide, with estimated cost savings and QALY gains.
5 context sentences(design, population, supporting numbers)
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4078845909
10Computer modelNot a test of Liraglutide aloneIn silicoEfficacy outcome
In lifetime simulations of the trial and NICE recommended populations, liraglutide had more modeled knee replacements than tirzepatide; the original tirzepatide-relative reduction was 29-46%, not an inverted estimate.
In plain wordsIn obesity or overweight simulations, liraglutide had more knee replacements than tirzepatide.
Peptide
Liraglutide
Outcome
Increaseknee replacements
Study
n: not reported in source
lifetime simulation model
Comparator
tirzepatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Published tirzepatide-relative knee-replacement reduction
29 to 46%
tirzepatide versus liraglutide; original orientation
Source sentences
Summary
In both populations, all doses of tirzepatide demonstrated reductions in at least five of seven complications compared to liraglutide, most notably for knee replacements (29-46% reduction) and diabetes (25-48% reduction).
6 context sentences(design, population, supporting numbers)
Summary · context
A subgroup analysis was performed in liraglutide's National Institute of Health and Care Excellence (NICE) recommended population (patients with a BMI of ≥ 35 kg/m² with non-diabetic hyperglycaemia and a high risk of cardiovascular disease [CVD]).
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4078845910
11Computer modelNot a test of Liraglutide aloneIn silicoEfficacy outcome
In lifetime simulations of the trial and NICE recommended populations, liraglutide had more modeled diabetes than tirzepatide; the original tirzepatide-relative reduction was 25-48%, not an inverted estimate.
In plain wordsIn obesity or overweight simulations, liraglutide had more diabetes than tirzepatide.
Peptide
Liraglutide
Outcome
Increasediabetes
Study
n: not reported in source
lifetime simulation model
Comparator
tirzepatide
Outcome group
Glycemic control · Metabolic and weight
Measurements
Published tirzepatide-relative diabetes reduction
25 to 48%
tirzepatide versus liraglutide; original orientation
Source sentences
Summary
In both populations, all doses of tirzepatide demonstrated reductions in at least five of seven complications compared to liraglutide, most notably for knee replacements (29-46% reduction) and diabetes (25-48% reduction).
6 context sentences(design, population, supporting numbers)
Summary · context
A subgroup analysis was performed in liraglutide's National Institute of Health and Care Excellence (NICE) recommended population (patients with a BMI of ≥ 35 kg/m² with non-diabetic hyperglycaemia and a high risk of cardiovascular disease [CVD]).
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4078845911
12Computer modelNot a test of Tirzepatide aloneIn silicoEfficacy outcome
In lifetime simulations of the obesity/overweight trial and NICE recommended populations, tirzepatide reduced at least five of seven modeled complications versus liraglutide; no unnamed individual complication estimate was supplied.
In plain wordsIn obesity or overweight simulations, tirzepatide reduced at least five of seven complications versus liraglutide.
Peptide
Tirzepatide
Outcome
DecreaseNumber of modeled complications with comparative reduction
Study
n: not reported in source
lifetime simulation model
Comparator
liraglutide
Outcome group
Overall treatment effect · Whole body
Source sentences
Summary
In both populations, all doses of tirzepatide demonstrated reductions in at least five of seven complications compared to liraglutide, most notably for knee replacements (29-46% reduction) and diabetes (25-48% reduction).
6 context sentences(design, population, supporting numbers)
Summary · context
A subgroup analysis was performed in liraglutide's National Institute of Health and Care Excellence (NICE) recommended population (patients with a BMI of ≥ 35 kg/m² with non-diabetic hyperglycaemia and a high risk of cardiovascular disease [CVD]).
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4078845912
13Computer modelNot a test of Liraglutide aloneIn silicoEfficacy outcome
In lifetime simulations of the obesity/overweight trial and NICE recommended populations, liraglutide had more modeled complications than tirzepatide for at least five of seven outcomes; no unnamed individual complication estimate was supplied.
In plain wordsIn obesity or overweight simulations, liraglutide had more complications than tirzepatide for at least five of seven outcomes.
Peptide
Liraglutide
Outcome
IncreaseNumber of modeled complications with comparative reduction
Study
n: not reported in source
lifetime simulation model
Comparator
tirzepatide
Outcome group
Overall treatment effect · Whole body
Source sentences
Summary
In both populations, all doses of tirzepatide demonstrated reductions in at least five of seven complications compared to liraglutide, most notably for knee replacements (29-46% reduction) and diabetes (25-48% reduction).
6 context sentences(design, population, supporting numbers)
Summary · context
A subgroup analysis was performed in liraglutide's National Institute of Health and Care Excellence (NICE) recommended population (patients with a BMI of ≥ 35 kg/m² with non-diabetic hyperglycaemia and a high risk of cardiovascular disease [CVD]).
Summary · context
A lifetime simulation model evaluated the costs and long-term clinical outcomes of each treatment.
Summary · context
The base-case population was aligned to the population from the SURMOUNT-1 trial.
Summary · context
Treatment efficacy was informed by a network meta-analysis.
Summary · context
tirzepatide (5 mg, 10 mg, 15 mg) compared to liraglutide (3 mg) both adjunct to a reduced-calorie diet and increased physical activity
Summary · context
in patients with a body mass index (BMI) ≥ 30 kg/m² (obesity), or with a BMI ≥ 27 to 2 (overweight) + ≥ 1 obesity-related complication ('trial population'
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4078845913

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.